NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee

Lund, Sweden, October 26, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the
Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 27
April 2017 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.
Shareholders are entitled to have a matter addressed by the Annual General
Meeting as long as their request has been received by the Board of Directors by
10 March 2017. The Board of Directors can be contacted by email at:
styrelsen@neurovive.com, or by post at: NeuroVive Pharmaceutical AB, FAO: Greg
Batcheller, Medicon Village, 223 81 Lund, Sweden.

The AGM on 28 April 2016 resolved that NeuroVive shall have a Nomination
Committee comprising one member for each of the three largest shareholders in
terms of voting rights based on ownership statistics maintained by Euroclear
Sweden AB as of 30 September 2016. If a shareholder does not exercise its right
to appoint a member, entitlement to appoint a member of the Nomination Committee
transfers to the shareholder who is the next largest shareholder in terms of
voting rights. The Nomination Committee’s period of office runs until a new
Nomination Committee has been appointed.

The Nomination Committee for the 2017 AGM comprises:

  · Anders Ermén, Chairman – nominated by Baulos Capital Belgium SA / Fredrik
Olsson
  · Michael Vickers – nominated by Maas Biolab LLC / Marcus Keep
  · Andreas Inghammar – nominated by Eskil Elmer

In total, the Nomination Committee represents some 19 % of the votes in
NeuroVive as of 30 September 2016.

The Nomination Committee’s task ahead of the AGM 2017 is to prepare proposals on
the following matters to present to the AGM for resolution:

  · Propose the Chairman of the AGM
  · Propose the number of Board members
  · Propose remuneration to Board members and remuneration to Committee members
  · Propose remuneration to the Auditors
  · Propose the Chairman of the Board and other Board members
  · Propose guidelines for appointing members of the Nomination Committee and
the assignments of the Nomination Committee
  · Propose remuneration to the members of the Nomination Committee

Shareholders wishing to make proposals on the above matters can contact the
Committee by email at: valberedningen@neurovive.com, or by post at: NeuroVive
Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81 Lund,
Sweden. In order for the Nomination Committee to consider the proposals received
with due care, proposals should be received by the Nomination Committee by no
later than 1 February 2017.

About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company
is committed to the discovery and development of medicines that preserve
mitochondrial integrity and function in areas of unmet medical need. NeuroVive
enhances the value of its projects in an organization that includes strong
international partnerships and a network of mitochondrial research institutions,
drug development and production expertise, as well as commercial partners.

NeuroVive has a project in clinical phase II development for the prevention of
moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan
drug designation in Europe and in the US. The R&D portfolio consists of several
late stage research programs in areas ranging from genetic mitochondrial
disorders to neurological and metabolic diseases.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also
traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com
Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or
ir.usa@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, at 08:30 a.m. CEST on October 26, 2016.